Key Insights

Highlights

Success Rate

78% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

12.2%

6 terminated out of 49 trials

Success Rate

77.8%

-8.8% vs benchmark

Late-Stage Pipeline

6%

3 trials in Phase 3/4

Results Transparency

43%

9 of 21 completed with results

Key Signals

9 with results78% success

Data Visualizations

Phase Distribution

40Total
Not Applicable (1)
Early P 1 (4)
P 1 (15)
P 2 (17)
P 3 (2)
P 4 (1)

Trial Status

Completed21
Recruiting13
Terminated6
Unknown6
Active Not Recruiting1
Suspended1

Trial Success Rate

77.8%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (49)

Showing 20 of 20 trials
NCT07388563Phase 1Suspended

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT06390319Phase 2Recruiting

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT03829540Phase 1RecruitingPrimary

CD4CAR for CD4+ Leukemia and Lymphoma

NCT05313243Phase 2RecruitingPrimary

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

NCT06131801Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

NCT05978141RecruitingPrimary

A Registry for People With T-cell Lymphoma

NCT04331119Phase 2TerminatedPrimary

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

NCT07538960Not Yet Recruiting

Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.

NCT05983965Phase 1TerminatedPrimary

Study of Tazemetostat in Lymphoid Malignancies

NCT07356245Phase 2RecruitingPrimary

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

NCT05996185Phase 2Recruiting

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

NCT04752826Phase 1Recruiting

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

NCT05665530Phase 1Completed

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

NCT06756308Phase 2RecruitingPrimary

A Study of Enasidenib in People With T-Cell Lymphoma

NCT02588651Phase 2CompletedPrimary

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

NCT04234048Phase 1RecruitingPrimary

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

NCT05442554Phase 4CompletedPrimary

A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

NCT06550427Recruiting

Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing

NCT03952078Phase 1Active Not RecruitingPrimary

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

NCT03792256Phase 1Completed

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Scroll to load more

Research Network

Activity Timeline